Table 1 Patient characteristics
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
Gender | Male | Male | Female | Female |
Initial tumor stage | pT4a pN1b M1 V1 Pn0 R1 | pT4a N1b L1 V1 Pn0 | pT4a N1a L0 V0 | pT3 N1b M0 |
Molecular pathology/RET | Sporadic, RET mutation p.M918T | Sporadic, RET mutation p.M918T | Unknown | Sporadic, RET negative |
Age at diagnosis | 40 years | 49 years | 47 years | 22 years |
Time since diagnosis | 13.8 months | 4.5 months | 113.4 months | 143.4 months |
Previous therapy | Thyroidectomy and neck dissection Vandetanib 300 mg/d | Thymus resection, thyroidectomy, and neck dissection radiation therapy | Thyroidectomy and neck dissection Atypical liver resection (metastases) | Thyroidectomy and neck dissection Vandetanib. 177Lu-DOTATOC (30 GBq). Radiation therapy neck |
Time since last tumor therapy | 0.5 months | 4.5 months | 11.2 months | 8.5 months |
Calcitonin | 114 pmol/l | 349 pmol/l | 153 pmol/l | 14,000 pmol/l |
CEA | 8.7 µg/l | 107 µg/l | 13.4 µg/l | 60.7 µg/l |
Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
|---|---|---|---|---|
Gender | Male | Male | Male | Male |
Initial tumor stage | pT3a N0 M1 | pT2 N1b M0 L1 V1 R0 | pT1b N1b cM0 L1 V1 Ro | T1a (m) N1 M0 |
Molecular pathology/RET | Sporadic, RET substitution p.G691S | MEN IIA, RET mutation p.C611Y | Germline negative, somatic unknown | MEN2, RET mutation p.S891A |
Age at diagnosis | 48 years | 40 years | 20 years | 35 years |
Time since diagnosis | 14.6 months | 41.8 months | 138.6 months | 178 months |
Previous therapy | Thyroidectomy and neck dissection Radiation therapy zoledronate | Thyroidectomy and neck dissection | Thyroidectomy and neck dissection PRRT (177Lu-DOTATATE, 30 GBq) radiation therapy | Thyroidectomy and neck dissection |
Time since last tumor therapy | 5.4 months | 41.8 months | 13.2 months | 178 months |
Calcitonin | 46.8 pmol/l | 441 pmol/l | 2840 pmol/l | 30 pmol/l |
CEA | 22.1 µg/l | 48.7 µg/l | 117 µg/l | 4 µg/l |